AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (OTCQB:BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today that a new audio interview with the Company is now available. The interview can be heard at https://smallcapvoice.com/3-24-17-smallcapvoice-interview-with-biocorrx-inc-bicx.
Brady Granier and Lourdes Felix called in to SmallCapVoice.com, Inc. to go over the exciting recent news for the Company. BICX recently announced it moved up to the OTCQB, their upcoming presentation at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29th, the positive preliminary data from preclinical studies evaluating BICX101, the validating work BICX is doing with the City of Anaheim to treat opioid and alcohol addiction, and more.
“We are very happy with the way things are progressing with the company’s initiatives,” stated Granier. “This interview restates some of our most recent developments and we look forward to providing more updates in the future.”
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for their ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit https://smallcapvoice.com/the-small-cap-daily-small-cap-newsletter/.
BioCorRx Inc. (BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
Crescendo Communications, LLC
(212) 671-1020 x304
Stuart T. Smith